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Abstract
Prominin-1, a heavily glycosylated pentaspan membrane protein, is mainly known for its function as a marker for (cancer)
stem cells, although it can also be detected on differentiated cells. Mouse prominin-1 expression is heavily regulated by
splicing in eight different variants. The function or the expression pattern of prominin-1 and its splice variants (SVs) is thus
far unknown. In this study, we analyzed the expression of the prominin-1 splice variants on mRNA level in several mouse
tissues and found a broad tissue expression of the majority of SVs, but a specific set of SVs had a much more restricted
expression profile. For instance, the testis expressed only SV3 and SV7. Moreover, SV8 was solely detected in the eye.
Intriguingly, prominin-1 knockout mice do not suffer from gross abnormalities, but do show signs of blindness, which
suggest that SV8 has a specific function in this tissue. In addition, databases searches for putative promoter regions in the
mouse prominin-1 gene revealed three potential promoter regions that could be linked to specific SVs. Interestingly, for
both SV7 and SV8, a specific potential promoter region could be identified. To conclude, the majority of mouse prominin-1
splice variants are widely expressed in mouse tissues. However, specific expression of a few variants, likely driven by specific
promoters, suggests distinct regulation and a potential important function for these variants in certain tissues.
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Introduction
The pentaspan membrane glycoprotein prominin-1 is widely
studied as a stem cell surface marker, both in human
[1,2,3,4,5,6,7,8] and mouse [9,10]. The human orthologue of
prominin-1, called CD133 has been used as a marker in a variety
of cancers to isolate cancer stem cells (CSCs) [1,2,3,4,5,6] as well
as hematopoietic stem cells [7,8]. Even though CD133 is broadly
used as a marker for (cancer) stem cells, the protein is also detected
in more differentiated cell types [11,12,13,14] and its exact
function of CD133 on (cancer) stem cells remains enigmatic.
However, it is quite evident that the expression of CD133 is
heavily regulated. Human CD133 is reported to have seven splice
variants (SVs) [15], which are under the control of five different
promoters [16]. In addition, the CD133 protein is glycosylated,
which, as we have shown before, is dependent on differentiation
status of the (cancer) cell [15].
As in human, the murine prominin-1 is also expressed in
differentiated cell types, shown by immunostainings for prominin-
1 on mouse tissues [9,14,17] as well as by a prominin-1
LacZ/+ mice,
that express LacZ in all prominin-1 expressing cells [9,10,14]. In
addition, colon tumors displayed an overall expression of
prominin-1 [14], suggesting that also in mouse, prominin-1
expression is not restricted to a (cancer) stem cell state.
Interestingly, prominin-1 did only mark the stem cell fraction in
the small intestine [9,10], indicating that the regulation of this
protein might be different in this tissue.
Like the human orthologue, the prominin-1 protein can
undergo heavy modification by glycosylation of its eight different
N-linked glycosylation sites. In addition, the existence of a
minimum of the eight SVs [10,17] point to the possibility that
mouse prominin-1 is highly regulated, although its promoters have
not been identified yet.
The alternative splicing mostly affects the cytoplasmic C-
terminus, resulting in four different C-terminal tails [17].
Differentially splicing of C-terminal tails suggest that promi-
nin-1 SVs might interact with distinct cytoplasmic binding
partners, potentially inducing specific signaling pathways and
thereby exerting separate functions. Although cytoplasmic
binding partners have not been identified for prominin-1, the
C-terminal tail of SV3-5 resembles a class II PDZ-binding
domain, while the C-terminal tail of SV1-2 and SV7-8 harbors
characteristics of a class I PDZ-binding domain [18]. PDZ-
binding domains are are thought to organize and regulate
signaling complexes via protein-protein interactions. In agree-
ment, a yeast two-hybrid screen showed that SV2 binds to a
PDZ-domain containing novel splice variant of the glutamate
receptor-interacting protein [18]. In human, Src and Fyn can
phosphorylate two tyrosine residues on the C-terminal part of
prominin-1 [19]. Altogether, this suggests that regulation of SV
expression might influence the (signaling) function of the
prominin-1 protein.
To gain more insight in the regulation of prominin-1 in mice,
we decided to study the prominin-1 SVs by analyzing their
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We found that most SVs were expressed in all tissues. However,
SV8 was specifically expressed in the eyes, whereas SV3 was only
found in the eyes, testis and colorectal (CRC) cell line CMT93. In
addition, SV7 was highly expressed in the testis. Interestingly, via
database searches, we were able to identify a specific potential
promoter region for both SV7 and SV8, suggesting that these two




Mice were maintained and experimented on in accordance with
the guidelines of and after approval by the Dier Experimenten
Commissie (DEC) of the Academic Medical Institute under permit
number DIX100578.
Mice tissues
Mouse tissues were obtained from C57BL/6J (WT) mice. The
APC Min colon and polyp were obtained from C57BL/6J-
ApcMin/J mice. After the animals were sacrificed, the tissues were
retrieved and snap-frozen in liquid nitrogen.
Cell lines
Mouse colorectal cell lines CMT93, C26, CC36 and MC38
[20] were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, Invitrogen) containing 8% fetal calf serum (FCS),
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 50 mM b-mercaptoethanol.
PCR
Total RNA was isolated from homogenized tissues by TRizol
extraction (Invitrogen) according to manufacturers’ protocol.
Quality and quantity of the RNA was measured on the Nanodrop
ND-1000 Spectrophotometer (Nanodrop Technologies). With
equal input of total RNA, cDNA was prepared with reverse
transcriptase III (Invitrogen) using random primers. The PCR
primers used for the splice variants are listed in Table 1. For
GAPDH, the following promers were used: forward 59- AT-
GTGTCCGTCGTGGATCTGA-39and reverse 59- ATGCCT-
GCTTCACCACCTTCT-39. The PCRs were run at either 53uC
or 54uC according to the following PCR program: 95uC for 4 min,
then cycling for 26–34 cycles with 95uC for 30 s, 53/54uC for
30 s, 54uC for 30 s 72uC for 30 s followed by a final elongation
step at 72uC for 10 min. PCRs were run on a 2% agarose gel.
Protein isolation, immunoblotting and treatment of
lysates with PNGaseF
For protein extraction, tissues were homogenized in lysis buffer
(20 mM Tris HCl, pH 7.4, 137 mM NaCl, 10% Glycerin, 1%
Triton-X-100, 2 mM EDTA, SPI and 1 mM PMSF). Protein
amounts were measured by BCA protein assay according to
manufacturer’s protocol. For deglycosylation experiments, protein
lysates (40 mg of protein) were incubated with glycoprotein
denaturing buffer (5% SDS, 0.4 M DTT) (New England Biolabs
#B1704S) for 10 min at 95uC. After denaturation, G7 buffer
(#B3704S) and 10% NP-40 (#B2704S) were added to the
samples. Subsequently, the samples were split in two. One aliquot
treated with 500 units/ml PNGase F whereas the other served as
an untreated control. Both aliquots were incubated overnight at
37uC. Per lane, 20 mg protein was loaded on 8% acryl amide gels
and consecutively blotted onto PDVF membrane. Unspecific
binding was blocked by 5% milk in PBS-0.1% Tween for 2 hours.
Blots were incubated with either rat-anti-mouse prominin-1
(13A4, eBioscience) or rabbit-anti-actin (I-19, sc-1616, Santa Cruz)
overnight in blocking buffer, subsequently washed in PBS
containing 0.2% Tween and incubated with HRP-labeled goat-
anti-rat IgG (I1306, Santa Cruz Biotechnology) or goat anti-rabbit
IgG (7074, Cell signaling) for 1 hour. For chemoluminescent
visualization, ECL from Amersham Biosciences was used. The
13A4 blots were developed by the use of films, whereas the actin
blots were developed by use of the FujiFilm LAS-3000.
mRNA and putative promoter database and computer
analyses
Analysis of mRNA and EST sequences was performed used the
National Center for Biotechnology Information database (http://
www.ncbi.nlm.nih.gov). Sequences were aligned in Vector NTI.
Putative promoter regions were analyzed by comparing them to
the genomice sequence (http://genome.ucsc.edu/). Potential
transcription factor binding sites on the putative promoter regions
were studied by using TFSearch (http://molsun1.cbrc.aist.go.
jp/research/db/TFSEARCH.html) and Alibaba (http://www.
gene-regulation.com/pub/programs/alibaba2/index.html). The
putative promoter region was analyzed for a potential CpG island
in CpG Island Searcher (http://cpgislands.usc.edu/cpg.aspx).
Results
Protein expression of prominin-1 splice variants in mouse
tissues
Prominin-1 is a five transmembrane protein consisting of an
extracellular N-terminal part, two large extracellular loops and an
Table 1. PCR primers used for discriminating prominin-1 splice variants.
Amplified region SV Forward primer Reverse primer
exon 2 – exon 25 1/2 59-CTGCATTCCATAACACTCCT-39 59-CAGGATTGTGAACACCATAT-39
exon 3a – exon 4b 1/2 59-GACATCTCAGTTGATTCCAAGG-39 59-CATGGCGCATTCTGCTTCTGC-39
exon 2 – exon 3b 2 59-ATGGCTCTCGTCTTCAGTGC-39 59-CTTCAGAGCCAAGACTATGA-39
exon 9 – exon 24a 3 59-CAACACTGTTACTGAAGTCGACAA-39 59-AAAGTGAAATGCCACAATCC-3
exon 8 – exon 11 4/5 59-CTCAATACCAACCTGAGCTC-39 59-GGAGCTAATGGAGTCCAAGG-39
exon 18 – exon 24a 6 59-ACAGAATATAAGAGCCATCC-39 59-TAAAGTGAAATGCCACATCC-39
exon 18 – exon 26 7/8 59-ACAGAATATAAGAGCCATCC-39 59-CAACTCCAGTTGTCAGTATCGAG-39
exon 19a – exon 23 8 59-ATTTGTGAGGGTGAGGAATA-39 59-ACATCCTCTGAATCCATCCT-39
doi:10.1371/journal.pone.0012325.t001
Prominin-1 Splice Variants
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been reported and this mostly affects the composition of
intracellular C-terminal tail [17,21]. In addition, some differen-
tially spliced exons are localized in regions that are transcribed as
part of the extracellular loops of the prominin-1 protein (Fig. 1A).
Altogether, differential splicing results in distinct protein sizes, with
different molecular weights and native iso-electric points (Table 2).
To gain more insight in the prominin-1 expression on protein,
several organs from wild type C57Bl\6 mice, like brain, eyes,
kidney, pancreas and testis and CRC cell lines like MC38, CC26,
CC36 and CMT93 were lysed and protein samples were loaded
on an immunoblot. Blotting with the 13A4 antibody detected the
prominin-1 protein as one or multiple bands in these organs
(Fig. 1B), ranging from ,90 to 116 kD. The protein’s apparent
molecular weight was much higher than predicted as in Table 2.
As prominin-1 is a highly glycosylated protein [17,22] with eight
potential N-linked glycosylation sites on two extracellular loops,
the difference between the detected molecular weight and the
predicted molecular weight was likely caused by glycosylation of
the prominin-1 protein. Although differential splicing does not
remove any N-linked glycosylation sites on the protein (Table 3),
the glycosylation of the prominin-1 protein might be dependent on
splicing and on the tissue in which it is expressed.
We therefore treated the lysates with PNGaseF to remove N-
linked glycans and analyzed the prominin-1 detection on an
immunoblot (Fig. 1C). Deglycosylation of the protein reduced, as
expected, the molecular weight to 90–98 kD. In addition, multiple
sizes of prominin-1 protein were visible on the blot, suggesting that
different tissues express distinct SVs. In principle, it should be
possible to discriminate between SV4/5 (,90 kD), SV6/7
(,92 kD), SV 3/8 (,94 kD) and SV1/2 (,97 kD) on a
immunoblot, but in practice, this was difficult to achieve, since
the difference in size were too small and different bands could be
linked to several SVs.
Altogether, these data indicate that protein detection of
prominin-1 SVs in different mouse tissue reveals the expression
of different SVs. However, it is not a sufficiently discriminative
approach to analyze differential usage of SVs. This is in part due
to differential glycosylation, but also due to relatively similar sizes
of some SVs after deglycosylation.
Multiple prominin-1 splice variants are expressed in
mouse organs
To obtain more insight into the prominin-1 SV expression in
mouse tissues, we decided to study their expression on mRNA
level. Aligning all mRNA and expressed sequence tags (ESTs)
sequences of prominin-1 from the NCBI database, we confirmed
the eight known SVs and their exon organization, as has been
published before (Fig. 2A) [18]. To evaluate the expression of the
different prominin-1 SVs in several tissues on mRNA level, we
designed several distinct primer sets to specifically amplify the
alternatively spliced regions (Table 3, Fig. 2C–H). We isolated
mRNA from several mouse tissues like eye, heart, pancreas, testis
and different parts of the gastrointestinal tract as confirmed by a
GAPDH PCR (Fig. 2B).
SV1 and SV2 were discriminated from the other SVs by using
primers that amplify the region from exon 2 to exon 25, which is
specifically expressed in SV1/2 (Fig. 2C). To discriminate between
SV1 and SV2, a nested PCR on this exon 2–25 PCR product was
performed, amplifying exon 3a to 4b (Fig. 2C), because SV1
splices out exon 3b, whereas SV2 retains this exon. The data from
this PCR showed that all tissues expressed SV1 as well as SV2, but
the eyes showed the highest SV2 expression. Although this nested
PCR is able to indicate if SV1 and SV2 are expressed in these
Figure 1. Expression of prominin 1 protein in several mouse tissues. A. Prominin-1 protein compared to the prominin-1 mRNA sequence.
Indicated is where the spliced regions of the mRNA are localized on the protein. None of the N-linked glycosylation sites are localized in any the
spliced exons. B. Immunoblot for prominin-1 on lysates of several mouse organs and murine CRC cell lines. As loading control, actin was used.
C. Lysates of several mouse organs were deglycosylated with PNGaseF and compared to untreated controls.
doi:10.1371/journal.pone.0012325.g001
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expression. This is illustrated by figure 2G, in which SV1 and SV2
are analyzed together in a direct PCR, which shows that there are
quite some expression differences between tissues, e.g. there is very
low expression of SV1/2 in the heart, liver and pancreas, whereas
the kidney and all parts of the gastrointestinal tract highly express
these SVs (Fig.2G).
The expression pattern of SV3 in mouse tissue was detected by
amplifying exon 9 to exon 24a, which is specifically expressed in
SV3 and the longer SV6 (Fig. 2D). Interestingly, the PCR data
showed that SV3 is exclusively expressed by the eyes, the testis and
CRC cell line CMT93 (Fig. 2D), suggesting that this SV has
restricted expression in mouse tissues.
SV4 and SV5 were analyzed together, due to only a minor
difference (15 bp) between the two variants. Also, these SVs have
been shown earlier to be unable to reach the cell surface and
therefore they are unlikely to have a prominent function. Primers
amplifying the region from exon 8 to exon 11 only were designed to
discriminate SV4/5 (which do not express exon 9) from the other
SVs and the PCR data showed that SV4/5 were expressed to a low
extend in all tissues (Fig. 2E). In addition, by comparing Figure 2F,
in which we analyze SV3-5 together, with Figure 2D, in which only
SV3 and SV6 were analyzed, we can conclude that the expression
level of SV4/5 is very low, consistent with the idea that these would
encode non-functional, potentially aberrant splice variants.
The SV6 expression pattern was analyzed by making use of the
fact that this splice variant retains intron 23. The retention will
induce an alternative stop codon, thereby inducing a shorter
protein, although the mRNA sequence will be longer due to this
retention. A PCR performed with primers amplifying exon 18 to
exon 24a can therefore discriminate between SV6 and SV3-5 and
showed that SV6 is expressed in a range of mouse tissues, but is
virtually absent in the heart, liver, stomach and testis (Fig. 2F).
These data are confirmed by the PCR performed in Figure 2D.
SV7 and 8 can be distinguished from the other SVs by using
primers that amplify from exon 18 to exon 26, because only SV7
and SV8 express exon 26 without exon 24b and 25. To
discriminate between SV7 and SV8, the PCR product includes
the differentially spliced exon 19a. SV7 was found to be expressed
by all tissues except for brain, heart, liver and pancreas (Fig. 2G).
SV8 was only found to be expressed in the eye. A separate PCR
was performed to confirm the SV8 expression profile, using
primers to amplify exon 19 (specifically expressed by SV8) to exon
23. This also showed that SV8 was only expressed in the eyes
(Fig. 2H).
Altogether, we can conclude from the prominin-1 mRNA SV
expression pattern (Fig. 2, Table 4) that 1) the heart, liver and
pancreas hardly express prominin-1; 2) SV1/2 are expressed in all
other tissues, although at varying levels; 3) SV4/5 are hardly
expressed in any of the tissues; 4) SV3 is only expressed in the eyes,
testis and CRC cell line CMT93; 5) SV8 is uniquely expressed in
the eyes; 6) the testis only expressed SV3 and SV7 and 7) the eye
expressed SV2, SV3, SV6 and SV8. Altogether,this suggests that
only SV3 and SV8 might have a more specific function in these
tissues dependent on their splicing. The other SVs probably have
either identical and/or redundant functions.
Putative promoter region of prominin-1
For human, it has been shown that multiple promoters exist that
can drive the expression of prominin-1 [16], although no
correlation was shown so far between specific promoter activity
and distinct SV expression. We hypothesized that mouse
prominin-1 is also regulated by several promoters. To this end,
all 59UTR of the different splice variants and the expressed
sequence tags (ESTs) as described in the NCBI database were
analyzed (Table 5). The alignment of the 59UTRs to the genomic
DNA revealed two extra exons in the 59UTR region of the
prominin-1 gene in addition to the previous identified exon
(Fig. 3A). One exon (exon A in Fig. 3A) was found approximately
7.2 kb upstream of exon 2. This exon was specifically found in the
59UTR of SV8. Exon 1, referred to as exon B in Fig. 3A, is located
6.9 kb upstream of exon 2, and seems to be mainly expressed in
the 59UTR of SV1 and SV2. A third exon (exon C), located 4.3 kb
upstream of exon 2, was only found in the 59UTR of SV7. SV3-6
did not contain a 59UTR as described on the NCBI database and
therefore, no additional 59UTR exons and putative promoter
Table 2. mRNA and protein details of prominin-1 splice variants.
Splice variant mRNA ORF (bp) Amino acids Protein (kD) Isoelectric point
1 2576 858 96,24 6,50
2 2603 867 97,13 6,68
3 2504 834 93,46 6,48
4 2414 804 90,00 6,81
5 2429 809 90,62 6,70
6 2471 823 92,24 6,44
7 2483 827 92,73 6,54
8 2528 842 94,49 6,91
doi:10.1371/journal.pone.0012325.t002









12 7 3 1 8
22 9 1 1 8
33 3 2 1 8
4 374 1 10
5 415 1 11
6 554 2 14
7 581 2 15
8 732 2 20
doi:10.1371/journal.pone.0012325.t003
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three found 59UTRs were linked to SVs that show specific
expression. Exon A was found in SV8, which is specifically
expressed in the eye. Exon B was found in SV7, which is expressed
in multiple tissues, but highly in the testis.
Next, we analyzed if these putative promoter regions contain
putative transcription factor binding sites, CpG islands or TATA
box regions. No TATA boxes were found, but a potential CpG
island was identified starting in putative promoter 2, spanning
approximately 1500 bp (data not shown). In addition, many
putative transcription factor binding sites were found in each of
the putative promoter regions (Fig. 3B and C).
To conclude, specific 59UTRs for SV1/2, SV7 and SV8 were
found, suggesting that these SVs can be alternatively regulated by
putative promoters. Different potential transcription factor binding
sites were found in each of the potential promoter regions,
indicating that the expression of these prominin-1 SVs might be
differentially regulated.
Discussion
In this study, we showed that several mouse organs express
multiple prominin-1 splice variants on mRNA, indicating that
these different variants probably have partially overlapping
functions. The distinct expression of SV3 and SV8 compared to
the other SVs hint towards a specific regulation of these SVs,
which suggests that these SVS have a unique role compared to the
other SVs. In literature, there are some indications that prominin-
1 SV expression is regulated. For example, SV1 is downregulated
in the brain during development, whereas SV3 is upregulated
[21], hinting towards specific regulation of SV expression. In
contrast, we did not detect SV3 expression in the adult brain.
Although this SV is almost identical to SV6 on both mRNA and
protein and could therefore easily been mistaken for SV6, our
PCR strategy was designed as such that the 39UTR of SV6, which
is not present in SV3, could be indentified by PCR. Therefore we
can conclude that SV6 is present in the brain and not SV3.
Although the exact function of prominin-1 and its SVs are thus
far unknown, it has been shown to play an important role in
morphogenesis of photoreceptor cells. For instance, patients that
harbor mutations in the prominin-1 gene suffer from retinal
degeneration [23,24,25]. In addition, prominin-1 deficient mice,
which are viable and fertile, display blindness due to complete
degeneration of mature photoreceptors [26]. Human CD133 was
found to be important for morphogenesis of new disk membranes
by interacting with actin (decreased by R373C mutation) and
protocadherin 21 (PCDH21). One of the missense mutations
found in patients with macular degeneration (R373C mutation)
decreases this interaction between actin and CD133 and causes
mislocalization of both CD133 and PCDH21 [25]. Interestingly,
SV8 was only found to be expressed in the eye and in none of the
other organs, which could potentially indicate that this SV may be
of importance to the development of the eye. SV8 is the only SV
that retains exon 19a, which is located in the second extracellular
loop. In human, a similar CD133 SV has not been identified yet.
As been shown for human [16], we found several distinct
putative promoter regions for the mouse prominin-1 gene.
Table 4. Expression of prominin-1 splice variants in mouse
tissues.
Organs SV 1 SV 2 SV 3 SV 4&5 SV 6 SV 7 SV 8
Bone Marrow VV X V VVX
Brain VV X V VXX
Eyes VV V V VXV
Heart VV X V XXX
Kidney VV X V VVX
Liver VV X V XXX
Lung VV X V VVX
Pancreas VV X V VXX
Stomach VV X V XVX
Testis VV V V XVX
Duodenum VV X V VVX
Ileum VV X V VVX
WT colon VV X V VVX
APC MIN colon VV X V VVX
Polip VV X V VVX
CMT93 VV V V VVX
Semi-quantitative analysis of prominin-1 splice variant PCR products. V means
that the SV is expressed in the tissue, X means that no PCR product is observed.
doi:10.1371/journal.pone.0012325.t004
Figure 2. Expression of prominin-1 splice variants in mouse organs. A. Schematic representation of prominin-1 splicing. Differentially
spliced exons are indicated by distinct colors. B. PCR performed on mouse tissues with primers amplifying GAPDH to confirm mRNA expression C–H
PCR data representing prominin-1 SV expression in mouse tissues. Each subpanel contains the analysed SVs, the location were the primers bind
(arrows) and the acquired products after performing the PCR. Primers sequences can be found in Table 3. C. PCR to specifically detect SV1 and SV2
with primers amplifying exon 2 to 25, only SV1 and SV2 products were obtained. Additionally, a nested PCR amplifying regions specific for SV1 and
SV2 was performed. N1 and N2 stand for nested primer sets. D. SV3 was discriminated from the other SVs by amplifying the region from exon 9 to
exon 24a. E. SV4 and SV5 were analysed together due to only a minor difference between these SVs (15 bp). By amplifying exon 8 to exon 11, SV4
and SV5 were discriminated from the other SVs. F. To specifically detect SV6, primers amplifying exon 18 to exon 24a were used, making use of the
fact that SV6 retains intron 23. G. SV7 and SV8 were discriminated from the other SVs by amplifying exon 18 to exon 26. H. The expression pattern of
SV8 was analyzed by using primers that bind the exon 19a, which is specifically expressed in SV8.
doi:10.1371/journal.pone.0012325.g002
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defined, the specific region found in the 59UTR of SV8, the SV
that is only expressed in the eye, hints towards a selective
regulation of this prominin-1 SV expression by an eye-selective
promoter. In addition, as shown for human CD133 promoters
[27,28] , regulation by methylation could explain for example the
selective expression of SV8 in the eye. Also, the many putative
binding sites for the transcription factor ‘heat shock factor’ (HSF)
in the putative promoter region 3, which appears to be linked to
the on testis highly expressed SV7, are striking. Especially as HSF
is known to be involved in chromatin reorganization in sperm
[29,30], suggesting that this transcription factor might regulate
prominin-1 SV7 expression in the testis.
We have shown that most of prominin-1 SVs are differentially
expressed in the majority of mouse tissues. Especially, SV3 and
SV8 expression is retained to specific tissues. Further studies will
have to reveal if these SVs have the capacity to interact with
specific binding partners or induce specific signaling. Specific
prominin-1 SV expression combined with selective promoter
usage hints towards a complex regulation of prominin-1 in mice,
as was found for humans. Additional studies, revealing the
function, ligand and/or binding partners of prominin-1 will shed
more light on the possible function of this heavy regulation.
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